| Literature DB >> 30479974 |
Hossein Elgafy1, Craig J Raberding2, Megan L Mooney2, Kyle A Andrews2, Joan M Duggan2.
Abstract
AIM: To define a ten-step protocol that reduced the incidence of surgical site infection in the spine surgery practice of the senior author and evaluate the support for each step based on current literature.Entities:
Keywords: Spine; Surgical site infections; Ten step protocol; Wound infections
Year: 2018 PMID: 30479974 PMCID: PMC6242729 DOI: 10.5312/wjo.v9.i11.271
Source DB: PubMed Journal: World J Orthop ISSN: 2218-5836
Studies from orthopedic literature evaluating preoperative hemoglobin A1c and surgical site infections
| Hikata et al[ | Retrospective cohort (IV) | Adult elective posterior instrumented thoracic and lumbar spinal arthrodesis | Non-diabetics ( | 10 (3.2%) SSI in non-diabetic group, No SSI in controlled diabetic group, 6 (35.3%) SSIs in uncontrolled diabetic group | Diabetes was an independent risk factor for SSI ( |
| Adams et al[ | Retrospective cohort (II) | Primary total knee arthroplasty | Non-diabetics ( | 216 (0.7%) deep infections in non-diabetics, 58 (1.2%) in controlled diabetics, and 13 (0.5%) in uncontrolled diabetics | No significant association between HbA1c level and deep infection |
| Harris et al[ | Retrospective cohort (IV) | Total joint arthroplasty | Controlled diabetics (HbA1c < 7.0; | Identical percentage of patients in both groups developed superficial and deep infections | Significant increase in overall complications ( |
| Iorio et al[ | Retrospective cohort (IV) | Primary or revision total hip or knee arthroplasty | Controlled diabetics (HbA1c < 7.0; | 5 (2.6%) infections in controlled diabetics, 5 (5.9%) infections in uncontrolled diabetics | Increased rate of infections in uncontrolled diabetics without statistical significance ( |
| Myers et al[ | Retrospective cohort (III) | Ankle and hindfoot fusions | Non-diabetics ( | 1 (1.4%) SSI in non-diabetics, 2 (6.7%) SSI in controlled diabetics, 12 (27.3%) SSI in uncontrolled diabetics | Significantly higher rate of SSI in uncontrolled vs controlled diabetics ( |
| Jämsen et al[ | Retrospective cohort (IV) | Primary total knee arthroplasty | Patients with HbA1c < 6.5 ( | No infections in patients with HbA1c < 6.5, 5 infections in patients with HbA1c ≥ 6.5 (2.84%) | Significant increase in infection rate in patients with HbA1c ≥ 6.5 ( |
| Lamloum et al[ | Retrospective cohort (IV) | Any orthopaedic surgical procedure | Controlled diabetics (HbA1c < 7.0; | 10 SSIs in controlled diabetics (12.5%), 33 SSIs in uncontrolled diabetics (13.9%) | No significant difference in SSI occurrence between the two groups ( |
| Marchant et al[ | Retrospective cohort (III) | Total joint arthroplasty | Non-diabetics ( | 3807 (0.41%) non-diabetics with infection, 405 (0.38%) controlled diabetics with infection, 47 (1.18%) uncontrolled diabetics with infection | Uncontrolled diabetics had a statistically significant increased rate of infection compared to patients without or with controlled diabetes ( |
HbA1c: Hemoglobin A1C; SSI: Surgical site infections.
Studies evaluating the use of vancomycin powder intraoperatively
| Ghobrial et al[ | Retrospective case series (IV) | Spinal procedures for degenerative disease, trauma, pain and scoliosis | Vancomycin powder(range from 1-6 g) applied to subfascial and epifascial layers but not to bone graft ( | 66 infections identified (6.7%) A number of gram-negative infections were encountered | Vancomycin may increase the incidence of gram-negative or polymicrobial spinal infections |
| Hill et al[ | Retrospective cohort (III) | Instrumented or non-instrumented posterior spine surgery in adults | Patients receiving 1-2 g vancomycin powder in surgical bed ( | 5 superficial infections in vancomycin powder group (3.3%), 5 superficial and 6 deep infections in control group (7.3%) | Significantly fewer deep infections in patients treated with vancomycin powder ( |
| Theologis et al[ | Retrospective cohort (III) | Complex adult spinal deformity reconstruction | Patients receiving 1-2 g vancomycin powder in subfascial space ( | 4 infections in first 90 d in treatment group (2.6%), 7 infections in first 90 d in control (10.9%) | Significantly fewer hospital readmissions within 90 d of surgery when using vancomycin powder ( |
| Caroom et al[ | Retrospective comparative study of prospectively collected data (II) | Multilevel posterior decompression and instrumentation for cervical spondylitic myelopathy | 1 g vancomycin powder applied subfascially along bone graft and instrumentation ( | Zero infections in vancomycin powder group (0%), 11 infections in control (15%) | Significant decrease in infection rate with use of vancomycin powder ( |
| Gans et al[ | Therapeutic retrospective cohort (II) | Pediatric spinal deformity surgery (fusion, growing rods, vertical expandable prosthetic titanium rib) | Patients received 1g vancomycin powder in surgical wound ( | 3 surgical site infections identified (3.4%) The postoperative systemic vancomycin levels remained undetectable. None of the patients experienced nephrotoxicity or red man syndrome | Local application of vancomycin powder is safe without significant changes in creatinine level or systemic vancomycin level |
| Kim et al[ | Retrospective cohort (IV) | Instrumented spinal fusion | Patients receiving 1 g vancomycin powder in surgical wound ( | Zero infections in vancomycin powder group (0%) 5 infections in control (12.5%) | Significant decrease in infection rate with use of vancomycin powder ( |
| Martin et al[ | Retrospective cohort (II) | Adult posterior thoracolumbar or lumbar instrumented fusion for spinal deformity | Patients receiving 2 g vancomycin powder in surgical wound ( | 8 infections in vancomycin powder group (5.1%), 8 infections in control (5.3%) | No significant difference in infection rate with use of vancomycin powder ( |
| Pahys et al[ | Therapeutic retrospective cohort (II) | Posterior cervical spine surgery | Group 1: Perioperative antibiotics alone ( | 9 infections in group 1 (1.86%), 1 infection in group 2 (0.3%), No infections in group 3 (0%) | Significant decrease in infections in both group 2 ( |
| Strom et al[ | Retrospective cohort (IV) | Instrumented and non-instrumented posterior lumbar laminectomy and fusion | Patients receiving 1 g vancomycin powder in surgical wound ( | Zero infections in vancomycin powder group (0%), 11 infections in control (11%) | Significant decrease in infection rate with use of vancomycin powder ( |
| Strom et al[ | Retrospective cohort (IV) | Posterior cervical fusion | Patients receiving 1 g vancomycin powder in surgical wound ( | 2 infections in vancomycin powder group (2.5%), 10 infections in control (10.9%) | Significant decrease in infection rate with use of vancomycin powder ( |
| Tubaki et al[ | Prospective randomized controlled trial (II) | Any primary spine surgery excluding biopsy or minimally invasive procedure | Patients receiving 1 g vancomycin powder in surgical wound ( | 7 infections in vancomycin powder group (1.61%), 8 infections in control (1.68%) | No significant difference in infection rate with use of vancomycin powder |
| Molinari et al[ | Retrospective case series (IV) | Any spine surgery | Patients receiving 1 g vancomycin powder in surgical wound ( | Fifteen infections identified (0.99%) | Low rate of deep spinal wound infection for both instrumented and uninstrumented cases |
| Sweet et al[ | Retrospective cohort (IV) | Thoracic or lumbar posterior instrumented fusion | Patients receiving 1 g vancomycin powder in bone graft and 1 g applied directly to deep and superficial wound ( | Two infections in vancomycin powder group (0.2%), Twenty-one infection in control (2.6%) | Significant decrease in infection rate with use of vancomycin powder ( |
| O’Neill et al[ | Retrospective cohort (IV) | Instrumented posterior spine fusion for traumatic injury | Patients receiving 1 g vancomycin powder in surgical wound ( | Zero infections in vancomycin powder group (0%), Seven infections in control (13%) | Significant decrease in infection rate with use of vancomycin powder ( |
Clinical orthopedic studies evaluating surgical wound irrigation before closure
| Yazdi et al[ | Prospective randomized controlled trial (I) | Arthroscopic ACL reconstruction | Irrigation with 0.9% normal saline and 80 mg/L gentamicin ( | One infection in gentamicin group (0.57%), Four infections in normal saline alone group (2.2%) | Decreased rate of infection when using gentamicin in irrigating solution ( |
| Brown et al[ | Retrospective cohort (IV) | Primary total hip or total knee arthroplasty | Soak wound with 500 mL 0.35% povidone-iodine followed by 1 L NS pulse lavage prior to closure ( | One infection in betadine group (0.15%), Eighteen infections in saline alone group (0.97%) | Significant decrease in 90-d infection rate when soaking surgical wound with betadine solution prior to closure ( |
| Chang et al[ | Prospective randomized controlled trial (I) | Instrumented lumbosacral posterolateral fusion for degenerative spinal disorder with segmental instability | Wounds irrigated with 0.35% povidone-iodine ( | No infections in povidone-iodine group, 4.8% infection rate in saline group | Overall infection rate was statistically significant when comparing betadine solution group with no betadine group ( |
| Cheng et al[ | Prospective randomized controlled trial (I) | Spinal decompression with or without fusion | Wounds irrigated with 0.35% povidone-iodine ( | No infections in povidone-iodine group, 3.5% infection rate in saline group | Overall infection rate was statistically significant when comparing betadine solution group with no betadine group ( |
ACL: Anterior cruciate ligament.